• Vivacta Biotechnology (Shanghai) Co., Ltd.

  Participated · Series A · Apr 2026

  Vivacta is developing next-generation in vivo CAR-T therapies, with its lead program GT801 focused on hematologic malignancies and autoimmune diseases. Early clinical data reported at ASH 2025 indicated promising safety and efficacy signals for GT801. The company plans to use new financing to advance GT801 clinical trials, pursue regulatory submission and approval, expand its research team and platform, and drive global expansion. Vivacta describes its investor base as a mix of global industrial capital and specialist biotech investors, and raised over US$50 million in its Series A and Series A+ financings. After the financing, representatives from Loyal Valley Capital and DC Global Ventures joined the board, signaling investor engagement in governance and strategy.

• Brise Pharma

  Led · Series A · Apr 2024

  Brise Pharmaceuticals is a Shanghai-based clinical-stage biopharmaceutical company developing innovative analgesic treatments for acute and chronic pain. Led by CEO Dr. Guochun Li, the company focuses on migraine, neuropathic and musculoskeletal pain. Brise has advanced two molecules to the clinical stage in the US and China. It employs biology-based drug development platforms centered on the Trigeminovascular System (TVS) and the Dorsal Root Ganglion (DRG). The company recently completed Pre-A and Pre-A+ financings totaling approximately $20M. Proceeds will be used to advance its product pipeline in preclinical and clinical stages and to further refine and validate its TVS and DRG platforms. 熙源安健医药（上海）有限公司 is developing a global-leading pipeline of innovative analgesic drugs focused on pain targets with clear human genetic and pathophysiologic rationale. The company pursues the optimal therapeutic modalities and dosing routes and builds its pipeline via self-R&D, collaboration and M&A. It plans to use flexible clinical strategies to broaden drug accessibility and commercial value. Management is also seeking partners in medical devices, digital therapeutics and health management to create integrated, long-term pain-management solutions. The company aims to establish commercial channels first in China and then expand overseas. CEO Li Guochun has prior experience running pain-innovation projects at a large U.S. pharma, and the team emphasizes translating deeper clinical understanding of pain into new therapies.

• JSAB Technologies

  Led · Series C · Apr 2024

  Anjian Semiconductor focuses on the research, design and sales of semiconductor power devices. Its main products include high-performance trench-gate field-stop IGBTs, shielded-gate trench MOSFETs, high-voltage MOSFETs and fast-recovery MOSFETs. These products are used widely in power management and motor drive systems. The company recently completed a Series C financing of over ¥200 million. Proceeds will be used to develop and mass-produce automotive-grade IGBT and SiC MOS product platforms and to expand automotive-grade IGBT and SiC module packaging lines. The company also plans to grow its sales and other talent teams and to increase operating cash reserves.

• varnotech

  Participated · Series B · Mar 2024

  Huanaotai Biotech is an innovative vaccine and adjuvant developer focused on novel vaccine and adjuvant product development. The company is building core technology platforms to drive updates and replacement of domestically marketed vaccines. Its stated core platforms include an adjuvant technology platform, a vector technology platform, and an antigen screening technology platform. Huanaotai describes its adjuvant platform as having the potential to be disruptive in the domestic vaccine field. The company announced completion of a RMB 600 million B round.

• Direct Drive Technology

  Led · Series B · Mar 2024

  Benmo Technology focuses on core components and robot platforms, building direct‑drive motors, sensors and drives alongside a wheel‑leg robot product line (TITA and M-series variants) for home, commercial, logistics and entertainment markets. The company has a strong R&D orientation, including a motor pre‑research team formed in 2023 that applied Haerbeck array magnetization to its direct‑drive motors, achieving more than 1.5× torque density versus traditional permanent‑magnet motors. Product innovations include compact M07 motors for service and education platforms, straight‑drive motor modules (M0501A/M0502A/M0604A) that cut costs by 50–60% versus traditional motor+gearbox solutions, and battery hot‑swap and Tower accessories that enable 24‑hour operation for TITA robots. Benmo says it will scale commercialization via a newly formed robotics business unit to accelerate a universal wheeled‑leg embodied intelligence platform and deepen industry partnerships and ecosystem build‑out. The company was founded in Hong Kong in 2018, moved operations to the Songshan Lake robotics industrial base in 2020, and is registered in Dongguan; it holds over 240 granted patents. Recent financing will be directed to technology R&D, product innovation, market expansion and automated production to boost delivery capacity and broaden its direct‑drive and robotics market positions.

No current team members are available.